Contact us
Close

Getting in touch

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean condimentum justo massa, ut dapibus nisl vestibulum ac. Vestibulum dapibus dui ac tortor gravida pellentesque. Nam ut velit non sapien vulputate volutpat in pretium dui. Mauris malesuada urna et metus dignissim, cursus tincidunt.

Clinical trials

A ‘clinical trial’ is a research study in which people agree to test a new treatment to prevent or improve a disease or medical condition. A clinical trial also looks at how participants react to the new treatment and if any unwanted effects occur. This helps to determine if the new treatment works, is safe, and is better than those that are already available. Many clinical trials also compare existing treatments or test new ways to use or combine existing treatments.

A.

Clinical Trial of Afabicin in Bone or Joint Infections due to Staphylococcus

In this study, a new antibiotic is tested as a potential treatment for Staph specific infections that no longer respond to other antibiotics. This antibiotic is called afabicin Definition afabicin (Debio 1450) is a first-in-class new antibiotic benefiting from both oral and intravenous (IV) formulations. It is a highly potent, Staphylococcus-selective antibiotic with a low propensity to develop resistance. This FabI inhibitor is also active against staphylococci strains which are resistant to the current standard-of-care antibiotics such as beta- lactams, vancomycin, daptomycin or linezolid. Debio 1450, perfectly suited to tackle several hard-to-treat infections, is now studied in Bone & Joint infections (BJIs) caused by staphylococci. More info . It is developed by Debiopharm International S.A (also called Sponsor). Afabicin has been designed to kill only Staph and not other bacteria.

Patients with the following indications will be included in the proposed study: Septic arthritis (including acute and chronic forms) or Osteomyelitis (including vertebral and long bone osteomyelitis whether hematogenous, contiguous, or associated with trauma).

The primary objective of this study is to determine the safety and tolerability of afabicin Definition afabicin (Debio 1450) is a first-in-class new antibiotic benefiting from both oral and intravenous (IV) formulations. It is a highly potent, Staphylococcus-selective antibiotic with a low propensity to develop resistance. This FabI inhibitor is also active against staphylococci strains which are resistant to the current standard-of-care antibiotics such as beta- lactams, vancomycin, daptomycin or linezolid. Debio 1450, perfectly suited to tackle several hard-to-treat infections, is now studied in Bone & Joint infections (BJIs) caused by staphylococci. More info .

Patients will be treated either with afabicin Definition afabicin (Debio 1450) is a first-in-class new antibiotic benefiting from both oral and intravenous (IV) formulations. It is a highly potent, Staphylococcus-selective antibiotic with a low propensity to develop resistance. This FabI inhibitor is also active against staphylococci strains which are resistant to the current standard-of-care antibiotics such as beta- lactams, vancomycin, daptomycin or linezolid. Debio 1450, perfectly suited to tackle several hard-to-treat infections, is now studied in Bone & Joint infections (BJIs) caused by staphylococci. More info , or with the comparator, meaning the standard antibiotic therapy which is currently recommended to treat staphylococcus infections. The comparator will be selected by the study doctor among the following: cefazolin, clindamycin, linezolid or vancomycin for the infusion treatment, and linezolid or clindamycin for the oral treatment.

Patients will be treated with infusion of afabicin Definition afabicin (Debio 1450) is a first-in-class new antibiotic benefiting from both oral and intravenous (IV) formulations. It is a highly potent, Staphylococcus-selective antibiotic with a low propensity to develop resistance. This FabI inhibitor is also active against staphylococci strains which are resistant to the current standard-of-care antibiotics such as beta- lactams, vancomycin, daptomycin or linezolid. Debio 1450, perfectly suited to tackle several hard-to-treat infections, is now studied in Bone & Joint infections (BJIs) caused by staphylococci. More info 160 mg BID (2 doses) for a minimum of 1 day and up to a maximum of 14 days (2 weeks), followed by a switch to oral afabicin Definition afabicin (Debio 1450) is a first-in-class new antibiotic benefiting from both oral and intravenous (IV) formulations. It is a highly potent, Staphylococcus-selective antibiotic with a low propensity to develop resistance. This FabI inhibitor is also active against staphylococci strains which are resistant to the current standard-of-care antibiotics such as beta- lactams, vancomycin, daptomycin or linezolid. Debio 1450, perfectly suited to tackle several hard-to-treat infections, is now studied in Bone & Joint infections (BJIs) caused by staphylococci. More info at a dose of 240 mg BID (2 doses) for the remaining treatment duration

Depending of the indication, patients will be recruited in 3 cohorts: In cohort 1 (notably Septic arthritis) patients will be treated with afabicin Definition afabicin (Debio 1450) is a first-in-class new antibiotic benefiting from both oral and intravenous (IV) formulations. It is a highly potent, Staphylococcus-selective antibiotic with a low propensity to develop resistance. This FabI inhibitor is also active against staphylococci strains which are resistant to the current standard-of-care antibiotics such as beta- lactams, vancomycin, daptomycin or linezolid. Debio 1450, perfectly suited to tackle several hard-to-treat infections, is now studied in Bone & Joint infections (BJIs) caused by staphylococci. More info for a maximum of 3 weeks. In cohort 2 for a maximum of 6 weeks and in cohort 3 (notably Osteomyelitis) for a maximum of 12 weeks. After the end of treatment, patients will be followed up for 12 weeks.

  • _Phases

    • P
    • M
B.

Talk with your medical doctor

If you are interested in participating in an upcoming clinical trial, ask your doctor if a clinical trial might be right for you. Your doctor knows both you and your health history, which is invaluable in making this decision. Your doctor can help you gather the information needed to locate a trial and help you identify what questions might be important to ask before deciding to participate. When you join a clinical trial, you will still receive care from your primary doctor for your overall health. Most trials are only for a limited time and only pertain to the condition being studied.

C.

Find the trials on the map

Back to the pathologies